Apellis to present five abstracts at ASRS Annual Scientific Meeting

Apellis Pharmaceuticals announced that six abstracts, five of which are oral presentations, will be presented at the American Society of Retina Specialists Annual Scientific Meeting to be held July 17 – 20 in Stockholm, Sweden. These data reinforce the robust efficacy and well-documented safety profile of SYFOVRE for patients with geographic atrophy secondary to age-related macular degeneration. “We look forward to sharing data that further demonstrate why SYFOVRE is the most chosen GA treatment by retina specialists, highlighting its ability to slow disease progression with increasing effects over time,” said Caroline Baumal, M.D., chief medical officer, Apellis. “We are thrilled to present results showing that SYFOVRE demonstrated a visual function benefit in a prespecified microperimetry endpoint at 36 months in GALE.”